Can I read Reply to Treglia et al.: ^123^I‐metaiodobenzylguanidine cardiac scintigraphy appears feasible despite proposed obstacles on EtoBox?

Reply to Treglia et al.: ^123^I‐metaiodobenzylguanidine cardiac scintigraphy appears feasible despite proposed obstacles by Donald R. Royall is a Medicine article available to read on EtoBox.

What is Reply to Treglia et al.: ^123^I‐metaiodobenzylguanidine cardiac scintigraphy appears feasible despite proposed obstacles about?

Although we are sympathetic to Reynolds and Slocum's concerns, 1 their editorial errs on several points. The authors cite deference to regulatory (presumably Food and Drug Administration) approval as a constraint. The FDA has long recognized broad physician discretion in using FDAapproved drugs or devices for indications as physicians see fit and has mechanisms for the use of unapproved drugs or devices. That physicians do not venture beyond approved indications may reflect reticence in the face of insurers or peers who misunderstand evidence-based medicine (EBM) by equating EBM with randomized control trials (RCTs). EBM recognizes many levels of evidence. 2 The current version of EBM as equivalent to RCTs fails to understand the epistemic basis underlying statistical approaches in RCTs, as their very structure renders them highly problematic as sole guides to therapy. 3 The alternative of undisciplined or unsubstantiated treatments is unappealing as well; however, Reynolds and Slocum similarly err in proposing that physicians choose treatments according to first principles of physiological mechanisms. Although this would be ideal, first principles are rarely known and when known,

Who reads Reply to Treglia et al.: ^123^I‐metaiodobenzylguanidine cardiac scintigraphy appears feasible despite proposed obstacles?

Author

Donald R. Royall

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 0885-3185)

Published

2011

Language

EN

Field

Medicine (Health Sciences)